CarnoSyn® Brands Showcasing TriBsyn™ at the 46th ESPEN Congress On Clinical Nutrition & Metabolism
Exhibition at ESPEN Congress: Natural Alternatives International, Inc. and CarnoSyn® Brands will showcase their new product TriBsyn™ at the 46th ESPEN Congress on Clinical Nutrition & Metabolism in Milan from September 7-10, 2024, highlighting its benefits for muscle vitality and cognitive performance without the common side effects of beta-alanine.
Broadened Product Offerings: The introduction of TriBsyn™, a "paresthesia-free" formula, allows NAI to expand its dietary supplement range, catering to various consumer needs including older adults and vegans, while also participating in the upcoming European Geriatric Medicine Society Congress in Valencia.
Trade with 70% Backtested Accuracy
Analyst Views on NAII
About NAII
About the author
CarnoSyn® 4X Launches with Fourfold Bioavailability Increase
- Bioavailability Boost: CarnoSyn® 4X's proprietary formulation delivers over four times the bioavailability of standard beta-alanine without the associated paresthesia, significantly enhancing user experience in sports nutrition and potentially attracting a broader consumer base.
- Market Expansion Potential: This innovation provides sports nutrition brands with a new way to deliver CarnoSyn® benefits more efficiently, lowering cost-in-use and facilitating product line extensions and new launches.
- Clinical Support Advantage: Backed by over 55 clinical studies, CarnoSyn® 4X maintains its status as the only beta-alanine with New Dietary Ingredient (NDI) status, reinforcing the brand's credibility in the sports nutrition market.
- Brand Trust Continuation: NAI President Kenneth Wolf stated that CarnoSyn® 4X represents the next evolution of the brand in sports nutrition, aiming to attract consumers who may have avoided beta-alanine due to tingling sensations, thereby further solidifying CarnoSyn® as a trusted performance signal.
Natural Alternatives International, Inc. Reports Q4 and Year-to-Date Results for Fiscal Year 2025
Financial Performance: Natural Alternatives International, Inc. reported a net loss of $7.2 million for Q4 FY 2025, compared to a loss of $1.9 million in the same quarter of the previous year, with net sales increasing by 15% to $33.9 million.
Annual Overview: For the fiscal year 2025, the company experienced a net loss of $13.6 million, up from $7.2 million in FY 2024, despite a 14% increase in annual net sales to $129.9 million.
Future Outlook: The company anticipates a net loss in the first half of FY 2026 but expects to achieve profitability in the second half, driven by growth in customer relationships and sales.
Operational Challenges: The net loss was attributed to underutilization of factory capacity, a valuation allowance against deferred tax assets, and litigation settlement costs, despite overall revenue growth.
Natural Alternatives International, Inc. Announces New Manufacturing Agreement with The Juice Plus+® Company
Partnership Extension: Natural Alternatives International, Inc. has extended its partnership with The Juice Plus+ Company through a new multi-year Manufacturing Agreement for their capsule and powder products sold globally.
Commitment to Quality: Both companies emphasize their long-standing relationship and commitment to delivering high-quality nutritional products backed by scientific research, aiming for mutual benefits from the contract extension.
Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results
Financial Performance: Natural Alternatives International, Inc. reported a net loss of $2.2 million for Q3 2025, despite a 14% increase in net sales to $28.8 million compared to the previous year, largely due to increased private-label contract manufacturing sales.
Operational Challenges: The company continues to face operational losses attributed to underutilization of factory capacities, decreased beta-alanine revenue, and rising operating expenses, while maintaining a cautious outlook on profitability for the upcoming fiscal year.
Natural Alternatives International and CarnoSyn® Brands Publish Clinical Research Demonstrating TriBsyn™ Delivering Exceptional Bioavailability, Increased Efficiency and Paresthesia Elimination
Clinical Trial Results: Natural Alternatives International, Inc. announced that their TriBsyn™ beta-alanine complex significantly increases bioavailability and efficiency while eliminating the common side effect of paresthesia, as published in the journal Food Hydrocolloids for Health.
Product Innovation: TriBsyn™, utilizing proprietary Hydro Oleo technology, offers a higher potency and better absorption of beta-alanine, making it suitable for active aging populations and those seeking enhanced muscle vitality and cognitive performance without discomfort.
CarnoSyn® Brands Announces New U.S. Distribution Agreement With B&D Nutritional Ingredients
New Distribution Partnership: Natural Alternatives International, Inc. has partnered with B&D Nutritional Ingredients to distribute its new carnosine booster, TriBsyn™, targeting the U.S. dietary supplement market.
Product Benefits: TriBsyn™ is designed to enhance beta-alanine absorption without causing the typical paresthesia sensation, aiming to benefit various consumer groups including older adults and those seeking cognitive and physical health support.
CarnoSyn® 4X Launches with Fourfold Bioavailability Increase
- Bioavailability Boost: CarnoSyn® 4X's proprietary formulation delivers over four times the bioavailability of standard beta-alanine without the associated paresthesia, significantly enhancing user experience in sports nutrition and potentially attracting a broader consumer base.
- Market Expansion Potential: This innovation provides sports nutrition brands with a new way to deliver CarnoSyn® benefits more efficiently, lowering cost-in-use and facilitating product line extensions and new launches.
- Clinical Support Advantage: Backed by over 55 clinical studies, CarnoSyn® 4X maintains its status as the only beta-alanine with New Dietary Ingredient (NDI) status, reinforcing the brand's credibility in the sports nutrition market.
- Brand Trust Continuation: NAI President Kenneth Wolf stated that CarnoSyn® 4X represents the next evolution of the brand in sports nutrition, aiming to attract consumers who may have avoided beta-alanine due to tingling sensations, thereby further solidifying CarnoSyn® as a trusted performance signal.
Natural Alternatives International, Inc. Reports Q4 and Year-to-Date Results for Fiscal Year 2025
Financial Performance: Natural Alternatives International, Inc. reported a net loss of $7.2 million for Q4 FY 2025, compared to a loss of $1.9 million in the same quarter of the previous year, with net sales increasing by 15% to $33.9 million.
Annual Overview: For the fiscal year 2025, the company experienced a net loss of $13.6 million, up from $7.2 million in FY 2024, despite a 14% increase in annual net sales to $129.9 million.
Future Outlook: The company anticipates a net loss in the first half of FY 2026 but expects to achieve profitability in the second half, driven by growth in customer relationships and sales.
Operational Challenges: The net loss was attributed to underutilization of factory capacity, a valuation allowance against deferred tax assets, and litigation settlement costs, despite overall revenue growth.
Natural Alternatives International, Inc. Announces New Manufacturing Agreement with The Juice Plus+® Company
Partnership Extension: Natural Alternatives International, Inc. has extended its partnership with The Juice Plus+ Company through a new multi-year Manufacturing Agreement for their capsule and powder products sold globally.
Commitment to Quality: Both companies emphasize their long-standing relationship and commitment to delivering high-quality nutritional products backed by scientific research, aiming for mutual benefits from the contract extension.
Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results
Financial Performance: Natural Alternatives International, Inc. reported a net loss of $2.2 million for Q3 2025, despite a 14% increase in net sales to $28.8 million compared to the previous year, largely due to increased private-label contract manufacturing sales.
Operational Challenges: The company continues to face operational losses attributed to underutilization of factory capacities, decreased beta-alanine revenue, and rising operating expenses, while maintaining a cautious outlook on profitability for the upcoming fiscal year.
Natural Alternatives International and CarnoSyn® Brands Publish Clinical Research Demonstrating TriBsyn™ Delivering Exceptional Bioavailability, Increased Efficiency and Paresthesia Elimination
Clinical Trial Results: Natural Alternatives International, Inc. announced that their TriBsyn™ beta-alanine complex significantly increases bioavailability and efficiency while eliminating the common side effect of paresthesia, as published in the journal Food Hydrocolloids for Health.
Product Innovation: TriBsyn™, utilizing proprietary Hydro Oleo technology, offers a higher potency and better absorption of beta-alanine, making it suitable for active aging populations and those seeking enhanced muscle vitality and cognitive performance without discomfort.
CarnoSyn® Brands Announces New U.S. Distribution Agreement With B&D Nutritional Ingredients
New Distribution Partnership: Natural Alternatives International, Inc. has partnered with B&D Nutritional Ingredients to distribute its new carnosine booster, TriBsyn™, targeting the U.S. dietary supplement market.
Product Benefits: TriBsyn™ is designed to enhance beta-alanine absorption without causing the typical paresthesia sensation, aiming to benefit various consumer groups including older adults and those seeking cognitive and physical health support.
